New FDA boss sends message on addictive opioids. Will this East Bay drug maker benefit?

In an apparent first step toward taking on the nation's opioid abuse epidemic, the Food and Drug Administration is asking Endo Pharmaceuticals to remove the opioid pain medication Opana ER from the market. If Endo complies with the FDA's Thursday request, it could be a boon for Impax Laboratories Inc., the Hayward manufacturer of a generic form of Opana ER before the drug was reformulated by Endo. “We are facing an opioid epidemic – a public health crisis — and we must take all necessary…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news